Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aspergillus antigens are a heterogeneous group of molecules, including polysaccharides like galactomannan and (1,3)-beta-D-glucan, and proteins such as the ribotoxin Asp f 1, which are produced by Aspergillus species [1][2]. These antigens are fundamental to the fungus's structural integrity and its ability to colonize and invade host tissues [3]. In a clinical context, they are primarily utilized as diagnostic biomarkers for invasive aspergillosis, where their detection in serum or bronchoalveolar lavage fluid indicates active infection [4]. Furthermore, these antigens are the causative agents of hypersensitivity in allergic bronchopulmonary aspergillosis (ABPA), making them targets for immunodiagnostics and potential desensitization therapies [5]. While most current antifungal drugs, such as echinocandins, target the synthesis of these antigens rather than the molecules themselves, the antigens remain central to monitoring treatment response and developing novel immunotherapies [6].
Inhibition of (1,3)-beta-D-glucan synthase; disruption of fungal cell membrane integrity; inhibition of ergosterol biosynthesis; immune-mediated detection and neutralization
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aspergillus antigen.